Cullinan Oncology Inc To Host CLN-081 Regulatory Update Webinar Transcript
Good afternoon, ladies and gentlemen, and welcome to Cullinan Oncology's CLN-081, Clinical and Regulatory Update Conference Call. As a reminder, this call is being recorded. Earlier today, the company issued a press release providing a clinical and regulatory update on its CLN-081 program. This press release, along with a slide deck that you may find helpful while you listen to this call, are available on the Events section of Cullinan's Investor Relations website at investors.cullinanoncology.com.
It is now my pleasure to turn the call over to Chad Messer, Vice President of Investor Relations at Cullinan Oncology.
Good morning, everyone, and thank you all for joining us for our update on the CLN-081 program. My name is Chad Messer, and I'm the Vice President of Investor Relations at Cullinan Oncology. Before we begin, I would like to remind you all of the safe harbor provisions outlined on Slide 2. During today's presentation, management will be making certain forward-looking statements, which are based on current information, assumptions and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |